文献速递淋巴瘤白血病

伊布替尼治疗慢性淋巴细胞白血病四因素预后模型

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
PubMed 文献 · J Clin Oncol · 2020-10-07

本研究利用II/III期试验中接受伊布替尼治疗的患者数据,通过多变量分析和机器学习算法开发并验证了一个基于TP53异常、既往治疗、β-2微球蛋白≥5 mg/L和乳酸脱氢酶>250 U/L的四因素预后模型。

要点

  • 四因素模型可于治疗开始时识别伊布替尼治疗失败高风险患者。
  • 高风险组3年PFS为47%,中风险74%,低风险87%。
  • 外部验证中高风险组Richter转化发生率为17%,低风险组为0%。

核心结论

  • TP53异常、既往治疗、β-2微球蛋白≥5 mg/L和乳酸脱氢酶>250 U/L是伊布替尼治疗CLL患者PFS和OS的独立不良预后因素。
  • 基于这四个因素的四因素预后模型可有效分层患者风险,并在内外部队列中验证。

研究设计与样本

  • 发现数据集来自II期和III期试验中接受伊布替尼治疗的患者,并分为发现队列和内部验证队列。
  • 外部验证队列包括84例参加研究者发起的II期试验的患者。
  • 对18项治疗前参数进行单变量分析,终点为PFS和OS。

主要发现

  • 模型在初治和复发/难治队列中分别应用时仍保持显著性。
  • 外部队列中,BTK和PLCG2突变的累积发生率与模型风险分组强相关。
  • 外部队列中,高风险组Richter转化发生率为17%,低风险组无患者发生。

关键数值与推荐

  • 预后模型评分:TP53异常、既往治疗、β-2微球蛋白≥5 mg/L、乳酸脱氢酶>250 U/L各计1分。
  • 风险分组:3-4分为高风险,2分为中风险,0-1分为低风险。

临床怎么用

  • 在伊布替尼治疗开始时,可依据四因素模型识别治疗失败高风险患者,并考虑参加临床试验。

局限性

  • 外部验证队列样本量较小(84例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for prognostication and risk-stratification are needed. PATIENTS AND METHODS: Patients treated with ibrutinib in phase II and III trials provided the discovery data set and were subdivided into discovery and internal validation cohorts. An external validation cohort included 84 patients enrolled in our investigator-initiated phase II trial. Univariable analysis of 18 pretreatment parameters was performed using PFS and overall survival (OS) end-points. Multivariable analysis and machine-learning algorithms identified four factors for a prognostic model that was validated in internal and external cohorts. RESULTS: Factors independently associated with inferior PFS and OS were as follows: TP53 aberration, prior treatment, β-2 microglobulin ≥ 5 mg/L, and lactate dehydrogenase > 250 U/L. Each of these four factors contributed one point to a prognostic model that stratified patients into three risk groups: three to four points, high risk; two points, intermediate risk; zero to one point, low risk. The 3-year PFS rates for all 804 patients combined were 47%, 74%, and 87% for the high-, the intermediate-, and the low-risk group, respectively (P < .0001). The 3-year OS rates were 63%, 83%, and 93%, respectively (P < .0001). The model remained significant when applied to treatment-naïve and relapsed/refractory cohorts individually. For 84 patients in the external cohort, BTK and PLCG2 mutations were tested cross-sectionally and at progression. The cumulative incidences of mutations were strongly correlated with the model. In the external cohort, Richter's transformation occurred in 17% of the high-risk group, and in no patient in the low-risk group. CONCLUSION: Patients at increased risk of ibrutinib failure can be identified at treatment initiation and considered for clinical trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ahn IE, Tian X, Ipe D, et al. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J Clin Oncol. 2020. PMID: 33026937. doi:10.1200/JCO.20.00979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。